MarginsXMarginsX
Home › Markets › Health Care › IBRX

ImmunityBio Inc. (IBRX)

IBRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.98
-0.66% on the day
Market cap
$6.4B
Mid cap
Revenue · 2025
$113.3M
+668.3% on 2024
Net income · 2025
-$351.4M
-310.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/0001326110-26-000030-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIBRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2015
SEC CIK0001326110
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$113.3M
Net income-$351.4M
Operating income-$256.0M
Net margin-310.2%
Operating margin-226.0%
Revenue growth+668.3%
Cash$88.3M
Total assets$501.9M
P/E (computed)Net income was not positive
P/S (computed)56.2×

Warning signs

Cash runway
1.9 months
$45.1M cash at September 30, 2026
Share count, 1 year
+8.0%
2025-10-30 to 2026-11-03 · +59.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 9, 2026
Insider net buying, 12 months
-$8.4M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support."
10-Q 2026-11-09
Cash and burn$45.1M cash; operating cash flow -$71.9M a quarter.Report 2026-09-30
Shares outstanding1,063,826,073 (2026-11-03); 984,965,179 a year earlier; 667,705,368 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Diego, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $8.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$48.8M-$184.6M-$75.3M$45.1MNo debt tags$182.6M10-Q 2026-11-09
Q2 2026
2026-06-30
$51.2M-$230.4M-$66.5M$75.7MNo debt tags$165.8M10-Q 2026-08-04
Q1 2026
2026-03-31
$44.2M-$632.8M-$75.4M$205.2M$884K$141.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$38.3M-$61.9M-$70.4M$88.3M$1.8M$113.3M10-K 2026-02-23
Q3 2025
2025-09-30
$32.1M-$67.3M-$68.9M$60.2M$2.6M$82.6M10-Q 2026-11-09
Q2 2025
2025-06-30
$26.4M-$92.6M-$79.7M$137.7MNo debt tags$56.6M10-Q 2026-08-04
Q1 2025
2025-03-31
$16.5M-$129.6M-$85.9M$60.7MNo debt tags$31.2M10-Q 2026-05-07
Q4 2024
2024-12-31
$7.6M-$59.2M-$85.1M$143.4M$1.2M$14.7M10-K 2026-02-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-12-29
Latest annual report10-K2026-02-23
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 557 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-30.3%
1 month-38.6%
3 months-21.3%
Year to date+204.0%
1 year+201.0%
From 52-week high-47.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
KODKodiak Sciences Inc$100.73-9.41%$6.6B
IMVTImmunovant Inc.$33.28-2.63%$6.9B
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
ADPTAdaptive Biotechnologies Corporation$27.87-4.03%$4.5B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier